US-based ophthalmic surgical devices provider New World Medical has received the US Food and Drug Administration (FDA) 510(k) approval for its VIA360 Surgical System.
The VIA360 Surgical System is designed to deliver viscoelastic fluid in controlled amounts during ophthalmic surgeries.
It is also indicated to cut trabecular meshwork tissue during trabeculectomy procedures
New World Medical said that the VIA360 system will support different surgical workflows, standalone procedures or those combined with cataract surgery.
New World Medical president and COO Khalid Mansour said: “The clearance of VIA360 marks another milestone in our mission to deliver innovative solutions that empower surgeons and improve the lives of patients globally.
“This system was developed in close collaboration with ophthalmic surgeons, addressing key challenges in surgery and providing greater control, precision, and flexibility.”
New World Medical said that the VIA360 Surgical System is equipped with intuitive features to optimise surgeon control.
The ActiveInject Technology ensures on-demand delivery of viscoelastic fluids, while the Smart Prime System optimises viscoelastic volume throughout the procedure.
The system’s rotatable cannula provides enhanced positioning and flexibility, allowing a single entry without full device rotation.
Its microcatheter is designed to advance up to 360 degrees, with microchannels configured to deliver viscoelastic fluid both forward and tangentially to targeted areas.
New World Medical plans to launch the VIA360 Surgical System immediately in the US market, to transform ophthalmic surgery practices with its advanced features.
Eye Centres of Racine & Kenosha president, ophthalmic surgeon and glaucoma specialist Inder Paul Singh said: “The VIA360 facilitates a targeted approach that is tailored to each patient’s individual needs.
“The technology elevates the efficiency of the procedure by allowing me to deliver viscoelastic exactly where and when it’s needed, with complete control at my fingertips.”
